Company news

Orexo AB news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Orexo reports encouraging bioavailability in first in vivo study of oral semaglutide formulation based on AmorphOX

October 14, 2026

Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice

August 31, 2026

Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships

June 9, 2026

Orexo announces positive outcome from an in-vivo study of OX390

May 19, 2026

Earnings Call Q1 2026 (engelska)

April 28, 2026

Earnings Call Q1 2026

April 28, 2026

Q1 2026 Interim Report MASTER

April 28, 2026

Q1 2026 Interim Report 2026

April 28, 2026

Orexo Q1 2026 Interim Report

April 28, 2026

Invitation to presentation of Orexo´s Q1 2026 Interim Report

April 21, 2026

Orexo publishes Annual Report for 2025

March 27, 2026

Orexo changes the organizational structure and management team to increase focus on development of new products

March 6, 2026

Orexo calls for early redemption of its outstanding senior secured social bonds 2024/2028

March 4, 2026

Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs

February 19, 2026

Orexo Interim Report Q4 2025, incl. Full Year Report

February 5, 2026

Dexcel Pharma USA Acquires US Rights to Zubsolv®

January 7, 2026

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

September 5, 2025

Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court

August 29, 2025

Orexo to present clinical data for OX640 at the EAACI Congress

June 2, 2025

Calls

The 5 newest of 11 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.